PRESS RELEASE: ReadyGo and Gemina Laboratories to Develop a Rapid Mycobacterium Tuberculosis Diagnostic Test

ReadyGo Diagnostics Ltd. (ReadyGo), a specialist in isothermal molecular diagnostics, today announced that it has entered into an assay development agreement with Gemina Laboratories Ltd. (Gemina), a Canadian company that specialises in fast, affordable and accurate diagnostic tests.

ReadyGo will develop, optimise and validate an assay for the detection of MTB for Gemina to run on ReadyGo’s off-grid isothermal diagnostic platform, Geo. The Geo platform provides rapid results in any location in under 30 minutes and is expected to play a crucial role in the diagnosis of MTB within near patient settings which would greatly improve patient management and outcome.

MTB is a highly infectious airborne disease. There were over 10 million MTB infections globally in 2021 resulting in 1.6 million deaths. In addition, it was estimated that 4 million infections (2 in every 5 cases) remain undiagnosed and patients do not access treatment which impairs the ability to control the disease. Diagnosis in low- to middle- income countries, where the disease is most prevalent, generally involves smear microscopy from sputum samples. However, there are significant limitations to these tests, especially in remote settings and in diagnosing certain patient demographics such as children and the elderly who have difficulties producing sputum.

The diagnosis of MTB is therefore a serious and challenging healthcare issue. The World Health Organisation (WHO) has recommended the use of molecular diagnostic tests which can accommodate the use of alternative sample types such as saliva which would make testing more accessible. ReadyGo’s partnership with Gemina aims to address these recommendations and provide a test that can replace smear microscopy with a simple saliva sample which would provide a sample to answer result anywhere within 30 minutes.

Brian Firth, CEO of Gemina, commented:

"I'm excited about our partnership with ReadyGo Diagnostics. Our goal at Gemina Labs is to create better diagnostic tests for respiratory diseases. We focus on tests that are effective at the front line of patient care whether that be in the field, the home or the primary clinic. For this reason we've been impressed by ReadyGo's platform, Geo and what it could mean for the diagnosis and treatment of tuberculosis. I'm really confident that by teaming up with ReadyGo, we'll be able to create a fast and accurate TB detection solution that can make a real difference in improving patient outcomes all around the world."

Ben Cobb, CEO of ReadyGo Diagnostics, added:

"I'm really excited about our partnership with Gemina to create a simple platform for diagnosing tuberculosis. Having worked in this field for a long time, I know that a low-cost triage tool that can replace smear microscopy is desperately needed, especially in places with limited resources. We are proud of the progress made so far, and we're committed to becoming the go-to development partner for companies looking to create simple, cost-effective molecular diagnostics for different settings." 

ReadyGo Diagnostics is a rapidly growing diagnostics company that designs, develops and commercialises novel sample collection devices and diagnostic platforms. Our proprietary technology molecular diagnostic platform, Geo, permits low cost decentralised testing in under 30 minutes. Snap™ transforms sample preparation by elegantly combining sample collection with sample processing into a single, user-friendly disposable to provide optimal and reproducible results using molecular, biochemical and lateral flow tests. Snapshot™ combines this sample collection and processing architecture with an integrated molecular test to provide an all in one solution for diagnostic testing.

About Gemina Laboratories Ltd.

Gemina Laboratories Ltd. is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses.

Read more

PRESS RELEASE: Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel

At the 33rd European Congress of Clinical Microbiology & Infectious Diseases (www.eccmid.org), Bruker Corporation announced its latest innovations for user-friendly, best-in-class diagnostic solutions for routine clinical microbiology and infection diagnostics laboratories.

1. Bruker introduces fast next-generation MALDI Biotyper® IVD Software

Microbial identification faster than ever: The MBT Compass HT IVD software provides a high sample throughput for microbial identification with time-to-result of ~5 minutes for 96 sample spots. Because of a fast sample target exchange, the MBT system can now analyze up to 600 samples per hour, while covering over 4,600 species in the reference library.

Microbial identification with optimal performance: The new IDealTune™, part of the MBT Compass HT IVD software, provides fully automated tuning of MALDI-TOF parameters within a sample run, delivering consistent data quality without user intervention. This seamless and effortless approach further increases performance, reproducibility, and up-time of the system.

2. Optimizing sample preparation for mycobacteria

As mycobacteria are challenging species in microbiology, an optimized sample preparation protocol is essential for robust results. The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media. The inactivation method for safe sample handling does not require boiling, but convenient incubation of the mycobacteria with an inactivation reagent at room temperature.

Dr. Arthur Pranada, Head of the Microbiology Division at MVZ Dr. Eberhard & Partner in Dortmund, stated: “During the last years the number of clinical samples with nontuberculous mycobacteria has increased, and reliable identification is important for an assessment of the clinical significance. The MBT Mycobacteria IVD Kit further simplifies the workflow for identification of nontuberculous mycobacteria by MALDI-TOF MS and reduces hands-on time. During the evaluation in our laboratory more than 96% of mycobacteria from solid and liquid media could be identified at a high-confidence level.”

Identifying challenging filamentous fungi

Identifying molds and multicellular fungi remains one of the most complex aspects of microbiology, because of varying culture conditions and colony morphology. The new MBT HT Filamentous Fungi IVD Module comes with an easy, yet powerful Mycelium Transfer (MyT) sample preparation procedure which together with a comprehensive reference library offers high identification success rates.

3. New LiquidArray® Gastrointestinal PCR Assay for Broad Syndromic Testing

Rapid culture-free pathogen identification: Bruker’s LiquidArray® technology offers rapid, multiplexed PCR pathogen detection for ease of implementation. Launched on the high-precision FluoroCycler® XT thermocycler, LiquidArray® combines innovative probe and thermocycling technologies with results-at-a-glance visualization for the simultaneous analysis of multiple targets from a single sample. The integrated FluoroSoftware® XT-IVD generates easy-to-interpret results, accelerating clinical decisions. The new LiquidArray® Gastrointestinal is a syndromic panel that enables the simultaneous detection of up to 26 pathogens causing gastroenteritis. LiquidArray® Gastrointestinal is validated on the GenoXtract® fleXT which streamlines extraction and PCR. This provides high-throughput clinical laboratories with a fully integrated workflow from sample to result.

Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division, commented: “With the introduction of our new IVD workflows, kits, software and reference libraries for mycobacteria and fungi, we further expand the applications of our established MALDI Biotyper® platform. This creates additional value for all current and future customers. The new LiquidArray® Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run.”

Read more

PRESS RELESE: Ad Astra Diagnostics Files FDA 510(k) Application for Rapid, Point-of-Care Analyzer to Detect Severe Infection, Including Sepsis

Ad Astra Diagnostics said Thursday it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the QScout RLD rapid-result hematology system to report white blood cell count, neutrophil-to-lymphocyte ratio, and counts of six white blood cell types in fingerstick or venous blood.

The QScout hematology platform is a rapid testing system that would operate at the point of care to provide measurements indicative of disease and infection. Such measurements include a ratio of two white blood cell types (neutrophil-to-lymphocyte ratio) and count of immature granulocytes.

Whole blood is added to a QScout RLD (rapid leukocyte differential) test, which contains a dried reagent that stains cells. When the test is inserted in the QScout Lab analyzer, an optical system takes images and an algorithm identifies cells in real time. Results are displayed in about two minutes.

The technology was funded in part by a federal contract with the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA).

Specifically, the funding was awarded by the BARDA Division of Research, Innovation, and Ventures for the earlier detection of severe infection, including sepsis in prehospital settings.

Specific levels of immature infection-fighting granulocytes can be one of the earliest markers for sepsis, the body's extreme response to infection.

The firm is seeking clearance of the system “for use at point of care where faster results can improve health outcomes and in the lab where it can improve efficiency,” Joy Parr Drach, AAD's president and CEO, said in a statement. “Meanwhile, we will continue discussions with partners who can help reach those healthcare settings."

Read more

PRESS RELEASE: TGV-Dx Announces Study Results Showing AtbFinder as Novel Paradigm for Rapid Antibiotic Susceptibility Testing for Multidrug-Resistant Infections

TGV-Dx, Inc, a development-stage in vitro diagnostics company developing advanced systems that improve selection of antibiotic therapies, has announced the results of a study on its lead diagnostic platform, AtbFinder®. The study on the advanced test system for optimal antibiotic therapy for people with severe pulmonary infections was published in the Journal of Clinical Microbiology.

The real-world study compared data and patient outcomes before and after implementation of the AtbFinder for the most hard-to-treat lung infection caused by multidrug-resistant pathogens in subjects with cystic fibrosis. As data showed, AtbFinder had successfully guided physicians to select the most effective antibiotic therapy that eradicated highly antibiotic resistant Pseudomonas aeruginosa bacteria, which led to decreased hospitalizations along with a two-fold reduction in systemic antibiotic therapy and enhanced overall patient outcomes.

AtbFinder is fundamentally different from other antimicrobial susceptibility tests as it, for the first time, selects antibiotics that target the entire bacterial community. The test offers a unique combination of culture-free phenotypic testing with unprecedented specificity and accuracy of antibiotic selection directly from the patient clinical sample. AtbFinder is an all-in-one prefabricated kit that screens 188 antibiotics and their combinations per patient sample and delivers results within just four hours, compared to up to 72 hours for conventional phenotypic tests. 

“While there are certain innovations in diagnostics for patients with sepsis, for patients with respiratory, skin-and soft tissue and urinary tract infections, the technology used now was developed in late 1980s. Since then, the rate of ineffective antibiotic selection has been increasing, and is approaching 40% for some diseases, which is believed to contribute to higher mortality rates,” said George Tetz, a scientific founder of the project. “AtbFinder is a new era in antimicrobial susceptibility testing that can potentially save thousands of lives and reduce healthcare costs. We are working to make AtbFinder available to physicians and patients, already this year.”

As data showed, physicians using AtbFinder were able, for the first time, to select therapeutic regimens that eradicated Pseudomonas aeruginosa, which is increasingly resistant to antibiotics and persisted in patients for years, despite hundreds of attempted antibiotic courses. In addition, lung functioning exhibited over 27% improvement with AtbFinder® identified therapy compared to conventional intervention.

Furthermore, once patients switched to antibiotic therapy selected with the AtbFinder, they no longer required hospitalization due to pulmonary exacerbations, as compared to several annual hospitalizations needed when the antibiotic selection was guided by conventional tests.

AtbFinder® is based on a recent discovery of a Novel Biology in which cells interact with each other using a previously unknown receptor system discovered by professors Victor and George Tetz from the Human Microbiology Institute in New York City.

“We are very excited that AtbFinder based on novel principles for antibiotic selection demonstrated such groundbreaking results,” said Victor Tetz, a scientific founder of the project. “Other tests ignore complex interbacterial interactions at the site of infection, which are the most critical in terms of antibiotic response prediction. In its selection of antibiotics, AtbFinder for the first time considers the interaction of not only the leading bacterial pathogens with antibiotics, but analyzes how the whole microbial community responds to the antibiotic assault. It’s like switching to a 3D image from 1 dimension.”

Scientists at TGV-Dx believe that these findings highlight the advantage of “targeting the entire microbial community ” to antibiotics utilized by AtbFinder for patients with severe and recurrent infections.

About TGV-Dx, Inc.

TGV-Dx, Inc. is an in vitro diagnostics company revolutionizing the way doctors select antibiotics. The AtbFinder® diagnostic test is an all-in-one prefabricated kit that is based on a new principle of antibiotic selection for patients with different bacterial infections. It delivers results within 4 hours, which is days faster than any conventional tests. The AtbFinder tests the largest menu of up to 188 antibiotics and combinations thereof, which is up to 15x more than conventional tests.

Read more

PRESS RELEASE: FDA Authorizes the First At-Home Test for COVID-19 and the Flu

The Food and Drug Administration issued an emergency use authorization for the first at-home test that can simultaneously detect both COVID-19 and the flu.

With a shallow nasal swab, the single-use kit can provide results within 30 minutes indicating whether a person is positive or negative for COVID, as well as influenza A and influenza B, which are two common strains of the flu.

People 14 and older can generally perform the test on themselves, the FDA says. Those between the ages of 2 and 13 can get results with the help of an adult.

Dr. Jeff Shuren, the director of the FDA's Center for Devices and Radiological Health, called the test as a "major milestone."

"We are eager to continue advancing greater access to at-home infectious disease testing to best support public health needs," Shuren said in a statement.

The test was developed by Lucira Health, a California-based company that was also the first to receive FDA approval for at-home rapid COVID tests back in 2020.

According to the FDA, in people showing symptoms, the Lucira home kit accurately detected 88.3% of COVID infections and 90.1% of influenza A infections. The test can identify influenza B in lab studies, the FDA said. But because there are not enough cases of the virus circulating in real-world settings, further testing will be required, officials said.

The FDA also warned that, similar to all rapid diagnostic tests, there is a risk of false positive and false negative results. The agency says individuals who test positive for COVID or the flu should take appropriate precautions and follow-up with a health care provider, while people who receive a negative result of either COVID or influenza B should confirm it with a molecular test preformed in a lab.

Individuals who test negative but continue to experience symptoms of fever, cough or shortness of breath should also follow up with their health care provider in case of other respiratory viruses, the FDA said.

The dual-purposed test comes after a surge of COVID, the flu and respiratory syncytial virus -- or RSV — that strained hospitals across the country last fall.

"The collective impact of COVID-19, flu and RSV underscore the importance of diagnostic tests for respiratory viruses," the FDA said in a statement.

Over the past few weeks, COVID-related deaths and hospitalizations have begun to fall, according to the latest data from the Centers for Disease Control and Prevention. Similarly, rates of flu and RSV-related hospitalizations have been going down, the CDC found.

Read more

PRESS RELEASE: Oxford University Scientists’ AI Diagnostic Test Accurately Identifies Known Respiratory Viruses in Minutes

Nicolas Shiaelis and Dr Nicole Robb, Oxford University scientists and co-founders of health tech company Pictura Bio, have developed a world-first diagnostic, test powered by artificial intelligence, that can identify known respiratory viruses such as influenza and COVID-19 within five minutes from just one nasal or throat swab.

Current tests are either lab based and time consuming or fast and less accurate. They are also limited, for instance, a lateral flow test only tests for one infection. This means illnesses are spread as infected people wait for results, or because they are unaware they are infected. These findings, published in peer-reviewed, scientific journal ACS Nano, demonstrate how machine learning can significantly improve the efficiency, accuracy and time taken to not only identify different types of viruses, but also differentiate between strains. This could help better control the spread of respiratory infections and alleviate pressure on the NHS and healthcare staff whilst reducing medical waste.

Shiaelis and Robb collaborated with the John Radcliffe Hospital to evaluate a new method that uses AI software to identify viruses. The ground-breaking testing technology combines molecular labelling, computer vision and machine learning to create a universal diagnostic imaging platform that looks directly at a patient sample and can identify which pathogen is present in a matter of seconds. Much like facial recognition software, but for germs.

Preliminary research demonstrated that this test could identify the COVID-19 virus in patient samples. But to develop this further, they wanted to determine if the test could be used to diagnose multiple respiratory infections.

In the study, researchers began by labelling viruses in over 200 clinical samples from John Radcliffe Hospital. Images of labelled samples were captured and processed by custom machine-learning software that is trained to recognise specific viruses by analysing their fluorescence labels, which show up differently for every virus because their surface size, shape and chemistry vary. The results show the technology is able to rapidly identify different types and strains of respiratory viruses, including flu and COVID-19, within five minutes and with >97% accuracy.

The scientists formed Pictura Bio to further develop this technology and are now looking for further investment to accelerate development and get it to the front line of healthcare.

Dr Nicole Robb, scientist and co-founder of Pictura Bio, comments: “Cases of respiratory infections in winter 2022/23 have hit record-breaking highs, increasing the number of people seeking medical help. This combined with the COVID-19 backlog, staff shortages, tighter budgets and an ageing population puts the NHS and its workforce under immense and unsustainable pressure.

“Pictura Bio’s simplified method of diagnostic testing is quicker and more cost-effective, accurate and future proof than any other tests currently available. If we want to detect a new virus, all we need to do is retrain the software to recognise it, rather than develop a whole new test. Our findings demonstrate the potential for this method to revolutionise viral diagnostics and our ability to control the spread of respiratory illnesses.”

Lead-author of the publication, co-founder and DPhil post-grad researcher at the University of Oxford, Nicolas Shiaelis, added: “It is inevitable that other COVID-like viruses will emerge. This reinforces the need for more advanced diagnostic testing technology so that we can reduce the impact of new viruses on public health and the NHS.”

The technology is now licensed by Pictura Bio which aims to turn the method into a diagnostic test by creating a dedicated imager and single-use cartridge for use in point-of-care testing, with limited input from the user. The team will also expand the number of viruses that the models are trained on and will eventually start looking at other pathogens, such as bacteria and fungi, in respiratory samples, blood and urine.

About Pictura Bio

Pictura Bio is a health-tech company that has developed the world’s first one-minute pathogen recognition platform. The software, like facial recognition for pathogens, is a universal testing platform, powered by AI, to provide accurate, digital imaging-based identification of infectious disease. The innovation encompasses two patented innovations - PIC-ID and IRIS. PIC-ID coats the lipid membrane whilst IRIS, a deep learning neural network, simultaneously analyses and classifies pathogens. It is a fundamentally different way of identifying ALL infectious agents and the company’s vision is to have a Lab in a Box for one minute testing on desktops in hospitals, GP surgeries and pharmacies around the world.

Pictura Bio’s solutions drive faster, simpler and more cost-effective testing than resource-consuming molecular diagnostics, changing how we treat disease. The technology will enable healthcare decision makers to revolutionise health care as we know it - bolstering the fight against antimicrobial resistance, reducing medical waste and limiting virus exposure.

PIC-ID and IRIS - the technology

The Pictura Bio team is focusing on packaging its PIC-ID technology into a simple desktop ‘lab in a box’, named IRIS (Instant Recognition Identification System) around the size of a domestic microwave, comprising a single-purpose high-powered fluorescent microscope and image capture and processing technology. This technology has reached proof of concept and is protected by patents and the team is now in the process of building the technology to scale this product for wider availability & adoption in the medical community. Today, PIC-ID is trained to spot enveloped viruses from respiratory samples, but the future holds boundless potential for how pathogens in samples are recognised.

The Neural Network is the database that IRIS checks against to identify a pathogen. This process ensures that as new tests and pathogens are learned by the network, it can be continuously rolled via a software update, instead of requiring new panels and the infrastructure to go with it.

Reference

Nicolas Shiaelis et al, Virus Detection and Identification in Minutes Using Single-Particle Imaging and Deep Learning, ACS Nano (2022). DOI: 10.1021/acsnano.2c10159

Read more

PRESS RELEASE: FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing

Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Next Generation Phenotyping (NGP) System — a rapid antibiotic susceptibility (AST) testing platform that provides targeted therapeutic results days faster than the current standard of care. 

The FDA clearance is for Selux Diagnostics' in vitro antimicrobial resistance test, which determines a bacteria's susceptibility to 14 specific antimicrobial agents on the Selux Gram-Positive Panel. Selux's NGP Gram-Negative panel is currently under review by the FDA. 

"This clearance represents a significant advance in infectious disease care and the fight to address antibiotic resistance. Our groundbreaking Selux NGP System holds the potential to save lives and decrease overreliance on broad-spectrum antibiotics, a key factor contributing to the rise of superbugs. We thank all our employees, partners, and advisors who contributed to this tremendous accomplishment," said Steve Lufkin, CEO of Selux Diagnostics.

"We have been waiting for true innovation in AST technologies to deliver rapid results that are accurate according to the latest FDA guidelines and include newly approved antibiotics," said James S. Lewis II, PharmD, FIDSA, co-director of antibiotic stewardship at Oregon Health and Science University, and chair, CLSI Antimicrobial Susceptibility Testing Subcommittee. "I am enthusiastic that the Selux NGP System addresses these critical needs and will become an essential tool for directing personalized therapies for infected patients."

Experts predict that without a significant change in today's treatment options, deaths from superbugs will surpass deaths from cancer by 2050. Selux is confronting this global health crisis head-on by redefining the speed and performance of AST, the critical diagnostic test that informs personalized antibiotic therapy.

Acknowledgment

This platform has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); and Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201800013C.

About Selux Diagnostics 

Selux Diagnostics is transforming patient care by accelerating the selection of personalized antimicrobial therapy for all Infectious Disease patients. This advance will save lives, shorten hospital stays, and combat the growing antibiotic resistance epidemic by decreasing the overuse of broad-spectrum agents. 

Read more

PRESS RELEASE: Revolutionary Ten-Second Test for Early Detection of Periodontal Disease and Pathogenic Bacteria in Dogs, Cats

PDX BIOTECH LLC today announced the official launch of OraStripdx, a revolutionary rapid test that can detect active periodontal disease in dogs and cats in ten seconds, with no anesthesia or sedation required. Each easy-to-use test strip changes color based on the concentration of thiols in the patient’s oral fluid. When a veterinarian or veterinary technician glides OraStripdx along the gumline of a dog or cat, thiols in the oral fluid will cause the test strip to change color, with the concentration of thiols reflecting periodontal disease activity.

“Periodontal disease is an invisible infection that causes needless suffering for millions of dogs and cats, so being able to test it this quickly and find it in its earliest stages is a major advantage to pet owners and their healthcare providers,” said John Beran, CEO of PDX BIOTECH, the parent company of OraStipdx. “In addition to periodontal disease itself causing pain, early detection can also serve as a warning sign of more serious disease.”

The performance of OraStripdx has been documented in peer-reviewed studies published in journals such as the Journal of the American Animal Hospital Association, the Journal of Veterinary Science & Technology and the Canadian Veterinary Journal. PDX BIOTECH has obtained five patents, and more than 250,000 tests have already been shipped to veterinary practices around the world.

The Science Behind OraStripdx 

Approximately 85% of dogs and cats have periodontal disease. This chronic and progressive disease impacting multiple organ systems develops in the gingival sulcus, an anatomic compartment between the tooth and gum that cannot be visualized in the awake patient. PDX BIOTECH has developed technology to detect the development of disease where it cannot be directly visualized.

In dogs, cats, and even humans, the concentration of thiols in oral fluid is directly related to periodontal disease activity. Thiols, also called “volatile sulfur compounds” or VSCs, are structurally similar to alcohols but have a sulfur atom in place of an oxygen atom. In periodontal disease, the gingival sulcus becomes anaerobic as it deepens into a periodontal pocket. Each periodontal pocket harbors millions of pathogens. The most prominent of these pathogens are anaerobic bacteria that produce thiols as end-products of their metabolism. These pathogens degrade gingival tissue and alveolar bone, leading to loss of tooth attachment and, ultimately, cardiovascular, renal and hepatic sequelae.

The OraStripdx test strip is pre-treated with a thiol detection reagent. After the strip is glided along the maxillary gingival margin of a canine or feline patient, its color will reflect the concentration of thiols in the patient’s oral fluid. No color change means no detectable thiols and no active periodontal disease. Any color change reflects periodontal disease activity. The more intense the color, the higher the concentration of thiols, and the greater the periodontal disease. These visual results are easy for veterinary professionals to interpret and easy for clients to understand.

Advantages of Early Detection 

Early detection of any disease can help prevent pain and suffering, as well as further progression of the condition. In peer-reviewed studies, OraStripdx was found to be significantly more effective than the visual awake exam in detecting active periodontal disease. This early detection enables timely intervention to prevent disease progression which may otherwise lead to tooth and bone loss as well as debilitating and life-threatening co-morbidities including cardiovascular, renal, and hepatic sequelae.

Early detection with OraStripdx also increases client compliance with veterinarian recommendations. In one peer-reviewed study, published in the Journal of Veterinary Science & Technology, routine use of the test in every wellness examination led to the following increases in client compliance with veterinarian recommendations: 

- 54% for professional cleaning under anesthesia

- 57% for dental radiology

- 80% for dental home care products.

Read more

PRESS RELEASE: ALiA BioTech’s One-stop Diagnostic Platform Brings Multiplex Testing to the Medical Front Line

Driven by the Covid-19 pandemic, the market for point-of-care testing (POCT) is seen to double in size compared to pre-pandemic levels. In this burgeoning field, multiplexing is the key technology differentiator. Increasing the number of simultaneous assays helps to identify the right biomarker, and thus reduces the cost and time it takes to quell any potential outbreak. ALiA BioTech group took on this challenge 10 years ago and is now ready to deploy a next-generation rapid diagnostic platform that can conduct multiplex testing in a single biochip within 15 minutes.

“It becomes very personal now,” said Kelvin Chiu, CEO. “Next time we sneeze or cough, we could be catching Covid-19, influenza, respiratory syncytial virus, or Streptococcus pneumoniae. A single test on our platform gives the fast track and accurate answer.”

ALiA’s Lab-on-Chip platform is a patented POCT that delivers up to 30 results from a single drop of body fluid, whether that be blood, serum, swab, or urine. Having completed research and development of its proprietary microfluidic and microarray technologies, ALiA is ready to scale up the manufacturing of multiplex products for different disease panels. The company’s pipeline will also direct POCT towards veterinary health and agri-food surveillance within the same platform.

ALiA analyser and its biochip panels for respiratory infection and tropical fever have obtained Europe’s CE marks, with the accredited ISO 13485 medical device quality management system.

The biotech firm is securing regulatory approval in other jurisdictions, including the United States, mainland China and Southeast Asia. The company anticipates global strategic partnerships in developing biochips for different disease panels and aims to deepen ties around product development and commercialisation. It also welcomes strategic partnerships to establish advanced manufacturing in the US, European Union and Asia-Pacific.

“Over the next five to 10 years, we shall develop more multiplex diseases panels and complete clinical trials and regulatory approval processes so that we can introduce more real-time rapid diagnostic panels that are critical to rescuing lives,” Chiu said.

Read more